Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)

Nasser H. Hanna, Suzanne E. Dahlberg, Jill M. Kolesar, Charu Aggarwal, Fred R. Hirsch, Suresh S. Ramalingam, Joan H. Schiller

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Fingerprint Dive into the research topics of 'Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)'. Together they form a unique fingerprint.

Medicine & Life Sciences